24 research outputs found
Regional Differences in Life Expectancy in Russia Through the Lens of Epidemiological Transition
Received 16 February 2024. Accepted 13 May 2024. Published online 21 July 2024.An immense territory of Russia with several climatic zones and, accordingly, a fundamentally different styles of life, inevitably results in pronounced varieties in the levels and structure of mortality across the regions of the country. Since the scale and sustainability of differences in mortality in Russia can be considered an entire epidemiological epoch, the evaluation of them through the lens of epidemiological transition seems methodologically appropriate. Regional differences are regarded as a kind of projection of evolution in time, though taking into account modern realities. The analysis of regional differences in mortality is based on such indicators as life expectancy, structure of mortality, i.e., predominantly endogenous to exogenous causes of death ratio, as well as the average age of death from predominantly endogenous causes calculated on the basis of life tables by cause of death. The study showed that according to the periodization of epidemiological transition only Moscow and St. Petersburg are at the final phase of the 3rd stage and are moving to the 4th stage of epidemiological development. Meanwhile, the burden of exogenous and preventable pathologies precludes the completion of the 3rd stage in the regions with high life expectancy according to Russian criteria. The stadial nature of epidemiologic development of Russian regions is currently conditioned by socio-economic and medical determinants, with more pressing medical determinants in regions with high and medium levels of life expectancy and socio-economic factors prevailing in regions with low life expectancy
ΠΠ°ΡΠΊΠ΅ΡΡ ΠΏΠΎΡΠ΅ΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ, Π»ΠΈΠΏΠΈΠ΄Π½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π° ΠΈ ΠΊΠ°ΡΠ±ΠΎΠ½ΠΈΠ»ΡΠ½ΠΎΠ³ΠΎ ΡΡΡΠ΅ΡΡΠ° Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ°Ρ Π°ΡΠ½ΡΠΌ Π΄ΠΈΠ°Π±Π΅ΡΠΎΠΌ I ΡΠΈΠΏΠ° ΠΈ ΡΠ°Π·Π½ΡΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ Π°Π»ΡΠ±ΡΠΌΠΈΠ½ΡΡΠΈΠΈ
The aim of this work was to study the levels of podocalyxin and Ξ²-2-microglobulin and parameters of lipid metabolism and carbonyl stress in type 1 diabetes mellitus (T1DM) patients with different levels of albuminuria.Materials and methods. 56 men of reproductive age with T1DM were divided into two groups: 24 patients with stage A1 albuminuria (group A1) and 32 patients with stage A2 albuminuria (group A2). The control group consisted of 28 healthy men. The levels of renal function markers, lipid metabolism parameters, and methylglyoxal were assessed using enzyme immunoassay and spectrophotometric and fluorometric methods.Results. Higher values for total cholesterol, triacylglycerol, and very-low-density lipoprotein medians in both groups A1 and A2 were found. In these groups, increased podocalyxin and methylglyoxal medians were revealed. Correlation analysis in the group A1 showed the presence of a relationship between the glomerular filtration rate (GFR) and creatinine. In the group A2, correlations between the generally accepted parameters of kidney injury (the albumin / creatinine ratio and GFR) and the duration of the disease and between GFR and the creatinine and methylglyoxal levels in the blood were identified. The podocalyxin level in this group correlated with the Ξ²2- microglobulin and methylglyoxal levels and lipid metabolism parameters. The level of Ξ²2-microglobulin correlated with the lipid metabolism parameters.Conclusion. Regardless of the level of albuminuria, men with T1DM had significantly increased levels of podocalyxin, lipid metabolism parameters, and methylglyoxal, as well as strong relationships between these parameters. The data of this study can be used for development of potential strategies for prevention and early treatment of diabetic nephropathy.Π¦Π΅Π»Ρ β ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Ρ ΠΏΠΎΠ΄ΠΎΠΊΠ°Π»ΠΈΠΊΡΠΈΠ½Π°, Ξ²-2-ΠΌΠΈΠΊΡΠΎΠ³Π»ΠΎΠ±ΡΠ»ΠΈΠ½Π°, ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ Π»ΠΈΠΏΠΈΠ΄Π½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π° ΠΈ ΠΊΠ°ΡΠ±ΠΎΠ½ΠΈΠ»ΡΠ½ΠΎΠ³ΠΎ ΡΡΡΠ΅ΡΡΠ° Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ°Ρ
Π°ΡΠ½ΡΠΌ Π΄ΠΈΠ°Π±Π΅ΡΠΎΠΌ (Π‘Π) I ΡΠΈΠΏΠ° ΠΈ ΡΠ°Π·Π½ΡΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ Π°Π»ΡΠ±ΡΠΌΠΈΠ½ΡΡΠΈΠΈ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ 56 ΠΌΡΠΆΡΠΈΠ½ ΡΠ΅ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ° Ρ Π‘Π I ΡΠΈΠΏΠ°, ΡΠ°Π·Π΄Π΅Π»Π΅Π½Π½ΡΡ
Π½Π° Π΄Π²Π΅ Π³ΡΡΠΏΠΏΡ: 24 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ Π°Π»ΡΠ±ΡΠΌΠΈΠ½ΡΡΠΈΠ΅ΠΉ ΡΡΠ°Π΄ΠΈΠΈ Π1 (Π³ΡΡΠΏΠΏΠ° Π1) ΠΈ 32 β Ρ Π°Π»ΡΠ±ΡΠΌΠΈΠ½ΡΡΠΈΠ΅ΠΉ ΡΡΠ°Π΄ΠΈΠΈ Π2 (Π³ΡΡΠΏΠΏΠ° Π2). ΠΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ Π³ΡΡΠΏΠΏΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 28 Π·Π΄ΠΎΡΠΎΠ²ΡΡ
ΠΌΡΠΆΡΠΈΠ½. ΠΡΠ΅Π½ΠΈΠ²Π°Π»ΡΡ ΡΡΠΎΠ²Π΅Π½Ρ ΠΏΠΎΡΠ΅ΡΠ½ΡΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ², ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΎΠ² Π»ΠΈΠΏΠΈΠ΄Π½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π° ΠΈ ΠΌΠ΅ΡΠΈΠ»Π³Π»ΠΈΠΎΠΊΡΠ°Π»Ρ (ΠΠ) Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΡΡ
, ΡΠΏΠ΅ΠΊΡΡΠΎΡΠΎΡΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ ΡΠ»ΡΠΎΡΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ².Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Ρ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠΈΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΡ ΠΌΠ΅Π΄ΠΈΠ°Π½ ΠΎΠ±ΡΠ΅Π³ΠΎ Ρ
ΠΎΠ»Π΅ΡΡΠ΅ΡΠΈΠ½Π°, ΡΡΠΈΠ°ΡΠΈΠ»Π³Π»ΠΈΡΠ΅ΡΠΈΠ΄ΠΎΠ² ΠΈ Π»ΠΈΠΏΠΎΠΏΡΠΎΡΠ΅ΠΈΠ΄ΠΎΠ² ΠΎΡΠ΅Π½Ρ Π½ΠΈΠ·ΠΊΠΎΠΉ ΠΏΠ»ΠΎΡΠ½ΠΎΡΡΠΈ Π² ΠΎΠ±Π΅ΠΈΡ
Π³ΡΡΠΏΠΏΠ°Ρ
Ρ Π‘Π I ΡΠΈΠΏΠ°. Π Π΄Π°Π½Π½ΡΡ
Π³ΡΡΠΏΠΏΠ°Ρ
ΠΎΡΠΌΠ΅ΡΠ°Π»ΠΈΡΡ ΡΠ°ΠΊΠΆΠ΅ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΡΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΡ ΠΌΠ΅Π΄ΠΈΠ°Π½Ρ ΠΏΠΎΠ΄ΠΎΠΊΠ°Π»ΠΈΠΊΡΠΈΠ½Π° ΠΈ ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ ΠΊΠ°ΡΠ±ΠΎΠ½ΠΈΠ»ΡΠ½ΠΎΠ³ΠΎ ΡΡΡΠ΅ΡΡΠ° β ΠΠ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΡΠΉ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΎΠ½Π½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· Π² Π³ΡΡΠΏΠΏΠ΅ Π1 ΠΏΠΎΠΊΠ°Π·Π°Π» Π½Π°Π»ΠΈΡΠΈΠ΅ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΡΡΠΎΠ²Π½Ρ ΡΠΊΠΎΡΠΎΡΡΠΈ ΠΊΠ»ΡΠ±ΠΎΡΠΊΠΎΠ²ΠΎΠΉ ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΠΈ (Π‘ΠΠ€) ΠΈ ΠΊΡΠ΅Π°ΡΠΈΠ½ΠΈΠ½Π°. Π Π³ΡΡΠΏΠΏΠ΅ Π2 ΠΎΡΠΌΠ΅ΡΠ°Π»ΠΈΡΡ ΡΠ²ΡΠ·ΠΈ ΠΎΠ±ΡΠ΅ΠΏΡΠΈΠ½ΡΡΡΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΏΠΎΡΠ΅ΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ (ΡΠΎΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΡ Π°Π»ΡΠ±ΡΠΌΠΈΠ½/ΠΊΡΠ΅Π°ΡΠΈΠ½ΠΈΠ½ ΠΈ Π‘ΠΠ€) Ρ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ Π‘ΠΠ€ Ρ ΡΡΠΎΠ²Π½Π΅ΠΌ ΠΊΡΠ΅Π°ΡΠΈΠ½ΠΈΠ½Π° ΠΈ ΠΠ. Π£ΡΠΎΠ²Π΅Π½Ρ ΠΏΠΎΠ΄ΠΎΠΊΠ°Π»ΠΈΠΊΡΠΈΠ½Π° Π² Π΄Π°Π½Π½ΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅ ΠΊΠΎΡΡΠ΅Π»ΠΈΡΠΎΠ²Π°Π» Ρ ΡΡΠΎΠ²Π½Π΅ΠΌ Ξ²2-ΠΌΠΈΠΊΡΠΎΠ³Π»ΠΎΠ±ΡΠ»ΠΈΠ½Π°, ΠΠ, ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ Π»ΠΈΠΏΠΈΠ΄Π½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π°; Ξ²2-ΠΌΠΈΠΊΡΠΎΠ³Π»ΠΎΠ±ΡΠ»ΠΈΠ½ ΠΈΠΌΠ΅Π» Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·ΠΈ Ρ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠ°ΠΌΠΈ Π»ΠΈΠΏΠΈΠ΄Π½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π°.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π£ ΠΌΡΠΆΡΠΈΠ½ Ρ Π‘Π I ΡΠΈΠΏΠ° Π²Π½Π΅ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΡΡΠΎΠ²Π½Ρ Π°Π»ΡΠ±ΡΠΌΠΈΠ½ΡΡΠΈΠΈ ΠΎΡΠΌΠ΅ΡΠ°ΡΡΡΡ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠΈΠΉ ΡΡΠΎΠ²Π΅Π½Ρ ΠΏΠΎΠ΄ΠΎΠΊΠ°Π»ΠΈΠΊΡΠΈΠ½Π°, ΡΠ²Π΅Π»ΠΈΡΠ΅Π½Π½ΡΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ Π»ΠΈΠΏΠΈΠ΄Π½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π° ΠΈ ΠΠ, Π° ΡΠ°ΠΊΠΆΠ΅ Π½Π°Π»ΠΈΡΠΈΠ΅ ΡΠ΅ΡΠ½ΡΡ
Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·Π΅ΠΉ ΠΌΠ΅ΠΆΠ΄Ρ ΡΡΠΈΠΌΠΈ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠ°ΠΌΠΈ, ΡΡΠΎ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΎ Π΄Π»Ρ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΡ
ΡΡΡΠ°ΡΠ΅Π³ΠΈΠΉ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ ΠΈ ΡΠ°Π½Π½Π΅ΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π΄ΠΈΠ°Π±Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π½Π΅ΡΡΠΎΠΏΠ°ΡΠΈΠΈ
ΠΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ Π½ΠΈΠ·ΠΊΠΎΠ±Π΅Π»ΠΊΠΎΠ²ΡΡ ΠΎΠ±ΠΎΠ³Π°ΡΠ΅Π½Π½ΡΡ ΠΊΡΠ°Ρ ΠΌΠ°Π»ΠΎΠΌΡΡΠ½ΡΡ ΠΏΡΠΎΠ΄ΡΠΊΡΠΎΠ² Π² Π΄ΠΈΠ΅ΡΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ ΡΠ΅Π½ΠΈΠ»ΠΊΠ΅ΡΠΎΠ½ΡΡΠΈΠ΅ΠΉ Π΄Π΅ΡΠ΅ΠΉ Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΡΡΠ°ΡΡΠ΅ 1 Π³ΠΎΠ΄Π°
Background. The nutrition of children with phenylketonuria includes specialized starch-based products, the range of which is constantly expanding. Our aim was to study the safety of the composition of starchy flakes enriched with a complex of fat-soluble vitamins, natural fruit and berry additives used in the food of children with phenylketonuria. Methods. The study included children under the age of 14 years who were compliant with the previously conducted hypophenylalanine diet, without acute infectious, severe somatic or neurological diseases. The investigated products (starch-rye, wheat, and wheat fruit flakes with a complex of provitamin A and vitamin E) were prescribed instead of previously used low-protein confectionery products in the amount of 20β25 g/day for children under 6 years, 30β40 g β for children aged 6 years and over. The products were given with the recommendation to use alternately, with a duration of at least 10 days, totally for 30 days of the study. The safety of the products was assessed by phenylalanine concentration in the blood (determined by the fluorimetric method). In addition, we assessed the organoleptic qualities of the products and the dynamics of physical development of children. Results. The study included 15 children, mean age 4.4 Β± 1.9 years. The initial concentration of phenylalanine in the blood varied from 1.6 to 3.9 mg%, the median β 2.2 mg% (2.0; 2.8). In 30 days after inclusion of starchy flakes in the diet, the content of phenylalanine in the blood did not change and was 2.5 mg% (2.2; 2.7); p = 0.859. The organoleptic properties of the products were rated Β«excellentΒ» by all patients and their parents (in children under 6 years, only according to the parentsβ assessment). The indicators of physical development did not change. There was no adverse events (allergic reactions, dyspepsia, refusal to take food). Conclusion. Introduction of new functional products β low-protein starchy flakes enriched with a vitamin complex and natural fruit and berry additives β in the diet of children with phenylketonuria allows to maintain the level of phenylalanine in the blood at the level of reference values.ΠΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠ΅. Π ΠΏΠΈΡΠ°Π½ΠΈΠΈ Π΄Π΅ΡΠ΅ΠΉ Ρ ΡΠ΅Π½ΠΈΠ»ΠΊΠ΅ΡΠΎΠ½ΡΡΠΈΠ΅ΠΉ ΡΠΈΡΠΎΠΊΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΡΡ ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ ΠΏΡΠΎΠ΄ΡΠΊΡΡ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΠΊΡΠ°Ρ
ΠΌΠ°Π»ΠΎΠ², Π°ΡΡΠΎΡΡΠΈΠΌΠ΅Π½Ρ ΠΊΠΎΡΠΎΡΡΡ
ΠΏΠΎΡΡΠΎΡΠ½Π½ΠΎ ΡΠ°ΡΡΠΈΡΡΠ΅ΡΡΡ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΈΠ·ΡΡΠΈΡΡ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ ΡΠΎΡΡΠ°Π²Π° Ρ
Π»ΠΎΠΏΡΠ΅Π² ΠΊΡΠ°Ρ
ΠΌΠ°Π»ΠΎΠΌΡΡΠ½ΡΡ
, ΠΎΠ±ΠΎΠ³Π°ΡΠ΅Π½Π½ΡΡ
ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠΎΠΌ ΠΆΠΈΡΠΎΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΡΡ
Π²ΠΈΡΠ°ΠΌΠΈΠ½ΠΎΠ², Π½Π°ΡΡΡΠ°Π»ΡΠ½ΡΠΌΠΈ ΠΏΠ»ΠΎΠ΄ΠΎΠ²ΡΠΌΠΈ ΠΈ ΡΠ³ΠΎΠ΄Π½ΡΠΌΠΈ Π΄ΠΎΠ±Π°Π²ΠΊΠ°ΠΌΠΈ, ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΠΌΡΡ
Π² ΠΏΠΈΡΠ΅ Π΄Π΅ΡΠ΅ΠΉ Ρ ΡΠ΅Π½ΠΈΠ»ΠΊΠ΅ΡΠΎΠ½ΡΡΠΈΠ΅ΠΉ.ΠΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ°Π»ΠΈ Π΄Π΅ΡΠ΅ΠΉ Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ Π΄ΠΎ 14 Π»Π΅Ρ, ΠΊΠΎΠΌΠΏΠ»Π°Π΅Π½ΡΠ½ΡΡ
ΠΊ ΡΠ°Π½Π΅Π΅ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠΌΠΎΠΉ Π³ΠΈΠΏΠΎΡΠ΅Π½ΠΈΠ»Π°Π»Π°Π½ΠΈΠ½ΠΎΠ²ΠΎΠΉ Π΄ΠΈΠ΅ΡΠ΅, Π±Π΅Π· ΠΎΡΡΡΡΡ
ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΎΠ½Π½ΡΡ
, ΡΡΠΆΠ΅Π»ΡΡ
ΡΠΎΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΠ»ΠΈ Π½Π΅Π²ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ. ΠΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΡΠ΅ ΠΏΡΠΎΠ΄ΡΠΊΡΡ β ΠΊΡΠ°Ρ
ΠΌΠ°Π»ΠΎΡΠΆΠ°Π½ΡΠ΅, ΠΏΡΠ΅Π½ΠΈΡΠ½ΡΠ΅ ΠΈ ΠΏΡΠ΅Π½ΠΈΡΠ½ΡΠ΅ ΠΏΠ»ΠΎΠ΄ΠΎΠ²ΠΎ-ΡΠ³ΠΎΠ΄Π½ΡΠ΅ Ρ
Π»ΠΎΠΏΡΡ Ρ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠΎΠΌ ΠΏΡΠΎΠ²ΠΈΡΠ°ΠΌΠΈΠ½Π° Π ΠΈ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° Π β Π½Π°Π·Π½Π°ΡΠ°Π»ΠΈ Π²Π·Π°ΠΌΠ΅Π½ ΠΏΡΠΈΠΌΠ΅Π½ΡΠ²ΡΠΈΡ
ΡΡ ΡΠ°Π½Π΅Π΅ Π½ΠΈΠ·ΠΊΠΎΠ±Π΅Π»ΠΊΠΎΠ²ΡΡ
ΠΊΠΎΠ½Π΄ΠΈΡΠ΅ΡΡΠΊΠΈΡ
ΠΈΠ·Π΄Π΅Π»ΠΈΠΉ Π² ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅ 20β25 Π³/ΡΡΡ Π΄Π΅ΡΡΠΌ ΠΌΠ»Π°Π΄ΡΠ΅ 6 Π»Π΅Ρ, ΠΏΠΎ 30β40 Π³ β Π΄Π΅ΡΡΠΌ, Π΄ΠΎΡΡΠΈΠ³ΡΠΈΡ
Π²ΠΎΠ·ΡΠ°ΡΡΠ° ΠΈΠ»ΠΈ ΡΡΠ°ΡΡΠ΅ 6 Π»Π΅Ρ. ΠΡΠΎΠ΄ΡΠΊΡΡ Π²ΡΠ΄Π°Π²Π°Π»ΠΈ Ρ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠ΅ΠΉ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°ΡΡ ΠΏΠΎΠΎΡΠ΅ΡΠ΅Π΄Π½ΠΎ, ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ Π½Π΅ ΠΌΠ΅Π½Π΅Π΅ 10 ΡΡΡ, Π²ΡΠ΅Π³ΠΎ Π½Π° 30 ΡΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. ΠΠ΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ ΠΏΡΠΎΠ΄ΡΠΊΡΠΎΠ² ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΏΠΎ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ ΡΠ΅Π½ΠΈΠ»Π°Π»Π°Π½ΠΈΠ½Π° Π² ΠΊΡΠΎΠ²ΠΈ (ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ ΡΠ»ΡΠΎΡΠΈΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ). ΠΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΎΡΠ³Π°Π½ΠΎΠ»Π΅ΠΏΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΏΡΠΎΠ΄ΡΠΊΡΠΎΠ² ΠΈ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΡ ΡΠΈΠ·ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π΄Π΅ΡΠ΅ΠΉ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠΈΠ»ΠΈ 15 Π΄Π΅ΡΠ΅ΠΉ, ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ 4,4Β±1,9 Π³ΠΎΠ΄Π°. ΠΡΡ
ΠΎΠ΄Π½Π°Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ ΡΠ΅Π½ΠΈΠ»Π°Π»Π°Π½ΠΈΠ½Π° Π² ΠΊΡΠΎΠ²ΠΈ Π²Π°ΡΡΠΈΡΠΎΠ²Π°Π»Π° ΠΎΡ 1,6 Π΄ΠΎ 3,9 ΠΌΠ³%, ΠΌΠ΅Π΄ΠΈΠ°Π½Π° β 2,2 ΠΌΠ³% (2,0; 2,8). Π§Π΅ΡΠ΅Π· 30 ΡΡΡ ΠΏΠΎΡΠ»Π΅ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΡ Π² ΡΠ°ΡΠΈΠΎΠ½ ΠΊΡΠ°Ρ
ΠΌΠ°Π»ΠΎΠΌΡΡΠ½ΡΡ
Ρ
Π»ΠΎΠΏΡΠ΅Π² ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ ΡΠ΅Π½ΠΈΠ»Π°Π»Π°Π½ΠΈΠ½Π° Π² ΠΊΡΠΎΠ²ΠΈ Π½Π΅ ΠΈΠ·ΠΌΠ΅Π½ΠΈΠ»ΠΎΡΡ ΠΈ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΎ 2,5 ΠΌΠ³% (2,2; 2,7); Ρ=0,859. ΠΡΠ³Π°Π½ΠΎΠ»Π΅ΠΏΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π° ΠΏΡΠΎΠ΄ΡΠΊΡΠΎΠ² Π±ΡΠ»ΠΈ ΠΎΡΠ΅Π½Π΅Π½Ρ Π½Π° Β«ΠΎΡΠ»ΠΈΡΠ½ΠΎΒ» Π²ΡΠ΅ΠΌΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌΠΈ ΠΈ ΠΈΡ
ΡΠΎΠ΄ΠΈΡΠ΅Π»ΡΠΌΠΈ (Ρ Π΄Π΅ΡΠ΅ΠΉ Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ Π΄ΠΎ 6 Π»Π΅Ρ β ΡΠΎΠ»ΡΠΊΠΎ ΡΠΎΠ³Π»Π°ΡΠ½ΠΎ ΠΎΡΠ΅Π½ΠΊΠ΅ ΡΠΎΠ΄ΠΈΡΠ΅Π»Π΅ΠΉ). ΠΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΡΠΈΠ·ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π½Π΅ ΠΈΠ·ΠΌΠ΅Π½ΠΈΠ»ΠΈΡΡ. ΠΠ΅ΠΆΠ΅Π»Π°ΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΠ²Π»Π΅Π½ΠΈΡ (Π°Π»Π»Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ΅Π°ΠΊΡΠΈΠΈ, Π΄ΠΈΡΠΏΠ΅ΠΏΡΠΈΠΈ, ΠΎΡΠΊΠ°Π· ΠΎΡ ΠΏΡΠΈΠ΅ΠΌΠ° ΠΏΡΠΎΠ΄ΡΠΊΡΠΎΠ²) Π½Π΅ Π·Π°ΡΠΈΠΊΡΠΈΡΠΎΠ²Π°Π½Ρ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ Π² ΡΠ°ΡΠΈΠΎΠ½ Π΄Π΅ΡΠ΅ΠΉ Ρ ΡΠ΅Π½ΠΈΠ»ΠΊΠ΅ΡΠΎΠ½ΡΡΠΈΠ΅ΠΉ Π½ΠΎΠ²ΡΡ
ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΠΏΡΠΎΠ΄ΡΠΊΡΠΎΠ² β Ρ
Π»ΠΎΠΏΡΠ΅Π² ΠΊΡΠ°Ρ
ΠΌΠ°Π»ΠΎΠΌΡΡΠ½ΡΡ
Π½ΠΈΠ·ΠΊΠΎΠ±Π΅Π»ΠΊΠΎΠ²ΡΡ
, ΠΎΠ±ΠΎΠ³Π°ΡΠ΅Π½Π½ΡΡ
Π²ΠΈΡΠ°ΠΌΠΈΠ½Π½ΡΠΌ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠΎΠΌ ΠΈ Π½Π°ΡΡΡΠ°Π»ΡΠ½ΡΠΌΠΈ ΠΏΠ»ΠΎΠ΄ΠΎΠ²ΡΠΌΠΈ ΠΈ ΡΠ³ΠΎΠ΄Π½ΡΠΌΠΈ Π΄ΠΎΠ±Π°Π²ΠΊΠ°ΠΌΠΈ, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΡΠΎΡ
ΡΠ°Π½ΡΡΡ ΡΡΠΎΠ²Π΅Π½Ρ ΡΠ΅Π½ΠΈΠ»Π°Π»Π°Π½ΠΈΠ½Π° Π² ΠΊΡΠΎΠ²ΠΈ Π½Π° ΡΡΠΎΠ²Π½Π΅ ΡΠ΅ΡΠ΅ΡΠ΅Π½ΡΠ½ΡΡ
Π·Π½Π°ΡΠ΅Π½ΠΈΠΉ.ΠΠ‘Π’ΠΠ§ΠΠΠ Π€ΠΠΠΠΠ‘ΠΠ ΠΠΠΠΠΠ― Π Π°Π±ΠΎΡΠ° Π²ΡΠΏΠΎΠ»Π½Π΅Π½Π° ΠΏΡΠΈ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠΊΠ΅ Π³ΡΠ°Π½ΡΠ° Π€Π΅Π΄Π΅ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π³ΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ Π½Π°ΡΡΠ½ΠΎΠ³ΠΎ ΡΡΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ Β«ΠΡΠ΅ΡΠΎΡΡΠΈΠΉΡΠΊΠΈΠΉ Π½Π°ΡΡΠ½ΠΎ-ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΡΠΊΠΈΠΉ ΠΈΠ½ΡΡΠΈΡΡΡ ΠΊΡΠ°Ρ
ΠΌΠ°Π»ΠΎΠΏΡΠΎΠ΄ΡΠΊΡΠΎΠ²Β» Π€Π΅Π΄Π΅ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π°Π³Π΅Π½ΡΡΡΠ²Π° Π½Π°ΡΡΠ½ΡΡ
ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΉ (ΠΠΎΡΠΊΠΎΠ²ΡΠΊΠ°Ρ ΠΎΠ±Π»Π°ΡΡΡ). ΠΠ»Ρ ΡΠ΅Π»Π΅ΠΉ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈΡΡ ΠΏΡΠΎΠ΄ΡΠΊΡΡ, Π±Π΅Π·Π²ΠΎΠ·ΠΌΠ΅Π·Π΄Π½ΠΎ ΠΏΡΠ΅Π΄ΠΎΡΡΠ°Π²Π»Π΅Π½Π½ΡΠ΅ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΡΠ΅Π»Π΅ΠΌ (ΠΎΠΏΡΡΠ½ΠΎΠ΅ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²ΠΎ Π€ΠΠΠ£ Β«ΠΠΠΠΠΒ» Π€ΠΠΠ).ΠΠΠΠ€ΠΠΠΠ’ ΠΠΠ’ΠΠ ΠΠ‘ΠΠ Π’.Π. ΠΠΎΡΠΎΠ²ΠΈΠΊ, Π.Π. Π‘Π΅ΠΌΡΠ½ΠΎΠ²Π°, Π.Π. ΠΡΠΊΠΎΡΠ½ΠΎΠ²Π°, Π.Π. ΠΠ²ΠΎΠ½ΠΊΠΎΠ²Π°, Π’.Π. ΠΡΡΡΠ΅Π²Π°, Π’.Π. Π‘ΡΠ΅ΠΏΠ°Π½ΠΎΠ²Π°, Π.Π. Π‘ΠΊΠ²ΠΎΡΡΠΎΠ²Π° β ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ Π½Π°ΡΡΠ½ΠΎ-ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΡΠΊΠΈΡ
ΡΠ°Π±ΠΎΡ ΠΏΡΠΈ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠΊΠ΅ ΠΊΠΎΠΌΠΏΠ°Π½ΠΈΠΉ Heinz, Semper, Π₯ΠΈΠΏΡΠΎΠΊΠ° ΠΡΡΡΠΈΡΠΈΠΎΠ½ ΠΡΡ ΠΠΈΠΌΠΈΡΠ΅Π΄. Π.Π. ΠΡΡΠ΅Π²Π°, Π.Π. Π ΠΎΡΠ»Π°Π²ΡΠ΅Π²Π°, Π.Π. ΠΠ΅Π²ΠΎΡΠΊΡΠ½, Π‘.Π’. ΠΡΠΊΠΎΠ²Π°, Π’.Π. ΠΠ°Π»ΠΈΠ½ΠΈΠ½Π°, Π‘.Π. ΠΠ°Π»ΠΈΠ½Π΅Π½ΠΊΠΎΠ²Π° ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠ΄ΠΈΠ»ΠΈ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ ΠΊΠΎΠ½ΡΠ»ΠΈΠΊΡΠ° ΠΈΠ½ΡΠ΅ΡΠ΅ΡΠΎΠ².ΠΠ«Π ΠΠΠΠΠΠ ΠΠ ΠΠΠΠΠ’ΠΠΠ¬ΠΠΠ‘Π’Π ΠΡΡΠ°ΠΆΠ°Π΅ΠΌ Π±Π»Π°Π³ΠΎΠ΄Π°ΡΠ½ΠΎΡΡΡ ΠΊ.ΠΌ.Π½. Π‘.Π. ΠΠ°Π»ΠΈΠ½Π΅Π½ΠΊΠΎΠ²ΠΎΠΉ (ΠΠΎΡΠΊΠΎΠ²ΡΠΊΠΈΠΉ ΠΎΠ±Π»Π°ΡΡΠ½ΠΎΠΉ Π½Π°ΡΡΠ½ΠΎ-ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΡΠΊΠΈΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΈΠ½ΡΡΠΈΡΡΡ ΠΈΠΌ. Π.Π€. ΠΠ»Π°Π΄ΠΈΠΌΠΈΡΡΠΊΠΎΠ³ΠΎ) Π·Π° ΡΡΠ°ΡΡΠΈΠ΅ Π² Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎΠΉ ΡΠ°ΡΡΠΈ Π΄Π°Π½Π½ΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ.Β
Ekaterinburg Atelier of Andrey Voronikhin
Π Π°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡΡΡ Π΅ΠΊΠ°ΡΠ΅ΡΠΈΠ½Π±ΡΡΠ³ΡΠΊΠΈΠ΅ ΡΠ°Π±ΠΎΡΡ, ΠΏΡΡΠΌΠΎ ΠΈ ΠΊΠΎΡΠ²Π΅Π½Π½ΠΎ ΡΠ²ΡΠ·Π°Π½Π½ΡΠ΅ Ρ ΠΈΠΌΠ΅Π½Π΅ΠΌ Π²ΡΠ΄Π°ΡΡΠ΅Π³ΠΎΡΡ ΡΡΡΡΠΊΠΎΠ³ΠΎ Π·ΠΎΠ΄ΡΠ΅Π³ΠΎ, Π²ΡΡΠΊΠ°Π·ΡΠ²Π°Π΅ΡΡΡ ΠΏΡΠ΅Π΄ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅ ΠΎ ΡΡΠΊΠΎΠ²ΠΎΠ΄ΡΡΠ΅ΠΉ ΡΠΎΠ»ΠΈ ΡΠ°ΠΌΠΎΠ³ΠΎ Π°ΡΡ
ΠΈΡΠ΅ΠΊΡΠΎΡΠ°, ΠΊΡΡΠ³Π° Π΅Π³ΠΎ Π΅Π΄ΠΈΠ½ΠΎΠΌΡΡΠ»Π΅Π½Π½ΠΈΠΊΠΎΠ² Π½Π° ΠΎΠ΄Π½ΠΎΠΌ ΠΈΠ· ΠΎΡΡΠ΅Π·ΠΊΠΎΠ² Π΄Π΅ΡΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΡΡΠ°Π»ΡΡΠΊΠΎΠΉ ΠΊΠ°Π·Π΅Π½Π½ΠΎΠΉ ΠΊΠ°ΠΌΠ½Π΅ΠΎΠ±ΡΠ°Π±ΠΎΡΠΊΠΈ.The article describes some works made in Yekaterinburg and either directly or indirectly connected with the name of the outstanding Russian architect. The author considers the architect's leading role and his partners' role in the creation thereof during a historic period in the state stone working of the Urals
PHARMACOLOGICAL CORRECTION OF CEREBRAL BLOOD FLOW DISTURBANCES IN WOMEN WITH ARTERIAL HYPERTENSION IN POSTMENOPAUSE
Aim: to study cerebral blood flow and cholesterol metabolism in menopausal women with arterial hypertension (AH); to evaluate dynamics of cerebral blood flow parameters and plasma lipid concentrations in these patients during 6-month antihypertensive and hypolipidemic therapy.Material and methods: 24 women with AH of I and II grade were examined. They were in postmenopausal period of life during 7,1Β±0,5 years. At the beginning of the study all women were prescribed moexipril as monotherapy, daily dose 7,5 β 15 mg. Patients with initial dislipidemia were prescribed lipid reducing drug atorvastatin in 10mg daily dose additionally to the antihypertensive therapy. Therefore all the patients were divided into two groups: I β monoteraphy with moexipril (13 people), II β combined therapy with moexipril and atorvastatin (11 people). At the beginning of the study and after 6 months all the patients passed through ultrasonic Dopplerography of vessels of head and neck, rheoencephalography, their lipoproteidogrammes were studied.Results: During 6-month therapy all the patients showed proved decrease in systolic and diastolic blood pressure, also positive dynamics of neuropsychological status, improvement in cerebral blood flow according to the results of Dopplerography of vessels and rheoencephalography. Normalization of plasma lipid spectrum was noted. More significant positive changes in cerebral hemodynamic parameters and plasma lipid spectrum were observed in patients, who received combined therapy with antihypertensive and lipid reducing drugs.Conclusion: Deterioration of cerebral hemodynamics is typical for women with long-lasting AH. The most positive influence on cerebral perfusion was received due to combined therapy with moexipril and atorvastatin
Leprosy in the Guise of Skin Tuberculosis β Complexities of Diagnostics
Objective: demonstration of the case of the leprosy late diagnosis at the female patient previously watched with the diagnosis Β«skin tuberculosisΒ». Materials and Methods. A 69 years old female patient watched from 2011 to 2016 with the diagnosis Β«skin tuberculosisΒ» and was cured with weak effect; in 2016 the diagnosis Β«skin tuberculosisΒ» was not confirmed. She undergone assessment at the State Research Centre for Dermatovenereology and Cosmetology of the Ministry of Health of the Russian Federation. The assessment included bacterioscopy of skin scrapings, pathomorphological studies of biopsy samples, molecular genetic testing. Results. On the grounds of complaints, medical history, data of surveying and physical examination, results of the clinical-laboratory studies the following diagnosis was stated: Β«dimorphous leprosy, leprosy BB (multibacillary leprosy, border line leprosy, active stage). Conclusion. The present observation indicates that the variety of leprosy clinical presentations and lack of suspicions on account of this ultra-rare disease lead to late diagnosis
Bladder cancer: treatment after progression. Results of the second retrospective analysis of data on the efficacy of vinflunin in patients with metastatic urothelial cancer in real clinical practice in Russia
Objective. There is the second generalized analysis of administration of vinflunine in real clinical practice in Russia.Materials and methods. This analysis gathered 15 patients with urothelial carcinoma treated using this medicine in 8 cancer centers in Russia. We assessed efficacy, safety profile of vinflunine in this subset of patients.Results. Clinical efficacy of vinflunine (complete response + partial response + stable disease) was 73.3 %, one patient demonstrated complete response. Median of response duration accounts for 3.8 months. Six-month and 1-year survival rate made up 93.3 %. Adverse events were observed in 53.5 %, with only one episode of neutropenia 4 grade.Conclusion. In our second analysis vinflunine was more effective than in randomized clinical trial and other studies from real practice in Europe. Thus, we confirm expediency to administer of vinflunine for metastatic urothelial carcinoma